Skip to main content

CORRECTION article

Front. Oncol. , 06 January 2023

Sec. Cancer Molecular Targets and Therapeutics

Volume 12 - 2022 | https://doi.org/10.3389/fonc.2022.1124912

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

This article is a correction to:

  1. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

    1. Read original article
Sunisa Prasopporn,Sunisa Prasopporn1,2Orawan Suppramote,Orawan Suppramote2,3Ben PonvilawanBen Ponvilawan2Chanette JamyuangChanette Jamyuang2Jantappapa ChanthercrobJantappapa Chanthercrob1Amphun ChaiboonchoeAmphun Chaiboonchoe1Pimkanya More-KrongPimkanya More-Krong1Kamonchanok KongsriKamonchanok Kongsri1Monthira SuntiparpluachaMonthira Suntiparpluacha1Rawisak ChanwatRawisak Chanwat4Krittiya KorphaisarnKrittiya Korphaisarn5Seiji OkadaSeiji Okada6Somponnat Sampattavanich,Somponnat Sampattavanich1,2Siwanon Jirawatnotai,*Siwanon Jirawatnotai1,2*
  • 1Siriraj Center of Research Excellence for Precision Medicine and Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 2Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 3Princess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand
  • 4HepatoPancreato-Biliary Surgery Unit, Department of Surgical Oncology, National Cancer Institute, Bangkok, Thailand
  • 5Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 6Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan

A Corrigendum on
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

by Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S and Jirawatnotai S (2022) 12:1021632. doi: 10.3389/fonc.2022.1021632

In the published article, there was an error in the Funding statement. There was one missing funding agency from our manuscript. The correct Funding statement appears below.

Funding

This study was funded by grants from the National Science and Technology Development Agency (NSTDA) of Thailand, the Japan Science and Technology Agency, and the National Institute of Allergy and Infectious Diseases of the United States as part of the e-ASIA Joint Research Program (e-ASIA JRP); the NSTDA (P-15-50208), the National Research Council of Thailand (NRCT) R016441034, the Advanced Research in Pharmacology Fund, Siriraj Foundation (D003421), and by Mahidol University (Basic Research Fund, and the grant of fiscal year 2022).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: SMAC mimetics, LCL161, Gemcitabine plus Cisplatin therapy, multidrug resistance, cholangiocarcinoma, acquired vulnerability

Citation: Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S and Jirawatnotai S (2023) Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma. Front. Oncol. 12:1124912. doi: 10.3389/fonc.2022.1124912

Received: 15 December 2022; Accepted: 19 December 2022;
Published: 06 January 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Prasopporn, Suppramote, Ponvilawan, Jamyuang, Chanthercrob, Chaiboonchoe, More-Krong, Kongsri, Suntiparpluacha, Chanwat, Korphaisarn, Okada, Sampattavanich and Jirawatnotai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Siwanon Jirawatnotai, U2l3YW5vbi5qaXJ3YXRub3RhaUBtYWhpZG9sLmFjLnRo

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

Man ultramarathon runner in the mountains he trains at sunset

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more